Strategy of Acquiring Small Firms Has Increased in Narcolepsy Market

Publisher: The Insight Partners

Narcolepsy Market To Account To US$ 4,537.9 Million By 2027 From US$ 2,026.8 Million In 2018. Jazz Pharmaceuticals, Inc., Novartis AG and TEVA Pharmaceuticals Industries - Notable Market Participants in Narcolepsy Market. 

The narcolepsy market is highly competitive in nature with considerable number of players, having a high level of consolidation overall revenue share. Most of the companies operating in the narcolepsy market are present globally and have wide distribution and sales network through partnerships or authorized dealers.

The most notable market participants are Bioprojet, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., Graymark Healthcare, Inc., Arena Pharmaceuticals, Inc., Shire (Acquired by Takeda), Ligand Pharmaceuticals, Inc., Novartis AG, Mylan N.V., and Shionogi Inc. occupying a considerable share of the market owing to their offerings to the market.

The global narcolepsy market accounted to US$ 2,026.8 Mn in 2018 and is expected to grow at a CAGR of 9.5% during the forecast period 2019 – 2027, to account to US$ 4,537.9 Mn by 2027.

Market leaders are involved in extensive research for the development of new drugs and therapeutics with better efficiency and treatment outcomes. For instance, in October 2018, Jazz Pharmaceuticals announced FDA approval of Xyrem (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness in pediatric narcolepsy patients.

The larger firms are adopting the strategy of acquiring small firms to enhance its product portfolio and expand its footprint in different geographies. Additionally various companies are also undergoing other strategic alliances such as acquisitions and others to garner their significance and remain competitive in the market. Jazz Pharmaceuticals announced FDA approval of Xyrem (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness in pediatric narcolepsy patients. Takeda Pharmaceutical Company Limited acquired Shire plc to expand its geographic footprint and leading position in Japan and the U.S.

Jazz Pharmaceuticals announced FDA acceptance of supplemental new drug application for Xyrem (sodium oxybate) to treat cataplexy and excessive daytime sleepiness in pediatric narcolepsy patients.